Fremont proteomics player Alamar Biosciences is making its move from quiet lab work to the public markets, filing to go public this week after a hiring blitz that added nearly 100 workers over the past two years. The company has been shifting from pure research to commercial sales, scaling its NULISA platform and rolling out larger multiplex panels for neurodegenerative and oncology research. Founder and CEO Yuling Luo, who has said a family death pushed her to pursue earlier cancer detection, is now steering the company through the paperwork for a public market debut.
As reported by the San Francisco Business Times, Alamar filed a registration related to an initial public offering but has not yet revealed how much it intends to raise. The outlet also highlighted the rapid hiring spree and noted that the filing lands just as the company is working to scale its commercial footprint in the East Bay.
Funding And Product Push
In February 2024, Alamar announced an oversubscribed 128 million dollar Series C round that brought total funding to nearly 250 million dollars and was pitched as fuel to speed up commercialization and expand its commercial teams. In its own release, Alamar Biosciences said the money would be used to grow sales and customer support operations as it ships its ARGO HT System and NULISA assays.
The product pipeline has been busy, too. Last Tuesday, the company launched the NULISAseq Neuro 220 Panel, a 220‑marker panel for Alzheimer's and Parkinson's research, according to a press release distributed via GlobeNewswire. The company is pitching it as its largest precision proteomics panel to date.
Hiring And Local Impact
The San Francisco Business Times reported that Alamar added nearly 100 workers in the past two years as it scaled up manufacturing and commercial operations in Fremont. The company's LinkedIn page currently lists roughly 196 employees, underscoring how quickly its footprint has grown at its Fremont campus at 47071 Bayside Parkway. The Business Times tracked the recent headcount surge, while Alamar's LinkedIn page reflects the latest tally.
What To Watch Next
The filing so far omits key details, such as timing and pricing, so investors, prospective customers, and employees will be watching for a full public SEC registration statement or follow-up disclosures. In recent releases, the company lists investor relations contacts and partnerships that highlight its pitch to pharmaceutical and academic partners. Both GlobeNewswire and Alamar Biosciences carry the company's most recent public statements and fundraising details.
